How are you taking part in this consultation?

You will not be able to change how you comment later.

You must be signed in to answer questions

  • Question on Consultation

    Has all of the relevant evidence been taken into account?

  • Question on Consultation

    Are the summaries of clinical and cost effectiveness reasonable interpretations of the evidence?

  • Question on Consultation

    Are the recommendations sound and a suitable basis for guidance to the NHS?

  • Question on Consultation

    Are there any aspects of the recommendations that need particular consideration to ensure we avoid unlawful discrimination against any group of people on the grounds of race, gender, disability, religion or belief, sexual orientation, age, gender reassignment, pregnancy and maternity?
The content on this page is not current guidance and is only for the purposes of the consultation process.

1 Recommendations

Closed for comments This consultation ended on at   Request commenting lead permission

2 Information about teprotumumab

Marketing authorisation indication

2.1

Teprotumumab (Tepezza, Amgen) is indicated 'in adults for the treatment of moderate to severe Thyroid Eye Disease (TED)'.

Price

2.3

The list price of teprotumumab 500-mg powder for concentrate for solution for infusion is commercial in confidence so cannot be reported here. The company has a commercial arrangement, which would have applied if teprotumumab had been recommended.

Carbon Reduction Plan

2.4

Information on the Carbon Reduction Plan for UK carbon emissions for Amgen will be included here when guidance is published.